retatrutide mechanism clinical trials Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Substack Series 3 of 6:

21 Headache outcomes may show more benefit over a longer trial duration, as during the relatively short time horizon of this trial other factors may also have contributed to headache such as medication overuse and opiate use, which occur in approximately one-third of IIH patients

However, if sulfur burps are accompanied by severe pain, vomiting, bloody stools, or fever, seek medical attention as these could indicate an underlying condition

Similarly, oral contraceptives may have reduced efficacy due to delayed absorption

Patients who lost the most weight regained the most in absolute terms

Retatrutide produces substantial overall weight loss but does not preferentially target visceral fat the way tesamorelin does

Ozempic, or semaglutide, helps control type 2 diabetes by acting like a hormone that lowers blood sugar